Byjosh Friedman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Byjosh friedman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Byjosh Friedman Today - Breaking & Trending Today

American Indian, Native Hawaiian data 'effectively nonexistent' in cancer trials

Most phase 2/phase 3 oncology clinical trials do not report American Indian or Alaska Native and Native Hawaiian or Other Pacific Islander racial categories in their studies, according to findings published in JAMA Health Forum. Additionally, information on Black or African American as well as Hispanic patients continues to lag. ....

United States , Mindy Valcarcel , Pubmed Embase , Byjosh Friedman , Kekoa Taparra , P Kekoa Taparra , Us Department Of Health , Human Services , Health Forum , Native Hawaiian , Alaska Native , African American , American Indian , Stanford Medicine , Affordable Care Act , Clinical Oncology , New England Journal ,

Osimertinib delays progression 'way more' than hoped in EGFR -mutant lung cancer

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO ....

United States , Josh Friedman , Sureshs Ramalingam , Mindy Valcarcel , Osimertinib Tagrisso , Julier Gralow , Davidr Spigel , Byjosh Friedman , Winship Cancer Institute Of Emory University , Sarah Cannon Research Institute , Winship Cancer Institute , Emory University ,

Isatuximab confers 'impressive' delay in multiple myeloma progression

CHICAGO — Isatuximab combined with a standard first-line treatment regimen significantly reduced the risk for disease progression and death in certain older individuals with multiple myeloma, results from a randomized phase 3 study showed.Additionally, patients with newly diagnosed, transplant-ineligible disease treated in the isatuximab (Sarclisa, Sanofi) arm of the IMROZ trial had ....

United States , Byjosh Friedman , Thierry Facon , Mindy Valcarcel , International Agency For Research On Cancer , Lille University Hospital , New England Journal , International Agency ,

Neoadjuvant immunotherapy 'the new standard' for resectable stage III melanoma

CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.Study participants who received neoadjuvant nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb) prior to therapeutic lymph ....

United States , Julier Gralow , Michaelc Lowe , Byjosh Friedman , Emory University School Of Medicine , Bristol Myers Squibb , Netherlands Cancer Institute , International Neoadjuvant Melanoma Consortium , Emory University School ,

Lorlatinib produces 'unprecedented' disease progression delay in ALK -positive lung cancer

CHICAGO — Lorlatinib delivered never-before-seen PFS results in adults with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to findings from a randomized phase 3 trial presented at ASCO Annual Meeting.Lorlatinib (Lorbrena, Pfizer) also drastically delayed disease progression and development of brain metastases compared with crizotinib (Xalkori, Pfizer). ....

United States , Lorlatinib Lorbrena , Mindy Valcarcel , Julier Gralow , Davidr Spigel , Byjosh Friedman , Peter Maccallum Cancer Center , Sarah Cannon Research Institute ,